CN104644915A - Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN104644915A CN104644915A CN201510034267.7A CN201510034267A CN104644915A CN 104644915 A CN104644915 A CN 104644915A CN 201510034267 A CN201510034267 A CN 201510034267A CN 104644915 A CN104644915 A CN 104644915A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- alcoholic
- radix
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating alcoholic liver diseases. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 172-258 parts of flower of kudzuvine, 128.8-193.2 parts of root of codonopsis pilosula, 85.6-128.4 parts of bighead atractylodes rhizome, 85.6-128.4 parts of poria cocos, 85.6-128.4 parts of bupleurum, 128.8-193.2 parts of white peony root, 128.8-193.2 parts of salviae miltiorrhizae, 128.8-193.2 parts of polygonum cuspidatum, 128.8-193.2 parts of rhizoma alismatis, 128.8-193.2 parts of hawthorn fruit, 128.8-193.2 parts of penthorum chinense pursh, 128.8-193.2 parts of hovenia dulcis thumb and 43.2-64.8 parts of liquorice. The invention also provides a preparation method and application of the pharmaceutical composition. The pharmaceutical composition disclosed by the invention is used for treating the diseases caused by alcoholic abuse and dependency, such as mild alcoholic injury, alcoholic fatty liver and alcoholic hepatitis, has good effects of dispelling the effects of alcohol, protecting the liver and lowering lipid and is obvious in curative effect of treating the alcoholic liver diseases. In addition, the medicine can obviously shorten the alcohol effect dispelling time by about 2 hours and is stable and reliable in drug effect and convenient to carry and take, and a novel selection is provided for clinical application.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of alcoholic liver disease, belong to drug world.
Background technology
Alcoholic liver disease (alcoholic liver disease, ALD) be liver injury caused by long-term heavy drinking and a series of pathological changes thereof, organize according to Chinese Medical Association's hepatopathy credit meeting fatty liver and alcoholic liver disease " the alcoholic liver disease practice guidelines " of in January, 2010 revision, ALD is clinical is divided into mild ALD, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis five kinds of pathological changes in various degree.ALD is the Etiological that western countries cause liver cirrhosis, is also one of ten large common causes of the death.In China, along with improving constantly of living standards of the people, social communication increase the increase etc. with operating pressure, the number of being addicted to drink also is increasing year by year.Data display according to investigations, the sickness rate of ALD in increasing trend year by year in China, has become the second largest hepatopathy being only second to viral hepatitis, therefore, the study on prevention of ALD has been caused to great attention and the concern of industry colleague.
Modern medicine is day by day deep to the research of the mechanism of ALD, generally believes its pathogenesis except the generation relating to ALD self and development, also closely related with nutritional status and genetic predisposition etc.Wherein, oxidative stress and lipid peroxidation double blow are thought to cause the pathogenetic key of alcoholic liver by Chinese scholars.But, to the treatment of this disease lacking special treatment means effectively always.In recent years, motherland's medical science, by the analysis of ALD etiology and pathogenesis and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, shows good prospect to the treatment of this disease.
Modern medicine is thought, the Major Risk Factors of ALD is relevant with drinking amount, drinking type, heredity, nutrition, hepatites virus infections etc.And its morbidity may be the coefficient result of many factors, as the impact of ethanol and metabolite thereof, the activation of Kupfer cell, endotoxin to the infringement of liver, oxidative stress and lipid peroxidation, humoral immunization and cellular immune abnormality, iron overload etc.Wherein, oxidative stress and this double blow of lipid peroxidation play a part key to ALD.Lack special treatment means effectively and medicine to the treatment of this disease, total Therapeutic Principle can be divided into alleviating alcohol addiction and nutritional support; Alleviate the order of severity of ALD, improve and reverse hepatic fibrosis; Improve already present secondary malnutrition; Several aspect such as symptomatic treatment.
Theory of Chinese medical science is thought, wine is the poisonous product of large heat, and crossing drink must imapirment of the spleen and stomach and liver and gall and diseases induced.Compendium of Material Medica is said: " drink less then QI and blood and ... polydipsia then kills a person momentariness." " General Treatise on the Cause and Symptoms of Diseases " think: " alcoholic strength is poisonous, and multiple large heat, drink too much, the meridians therefore pyretic toxicity air infiltration overflows.Overflow internal organs, and sick also all." Jing-Yue Complete Works says: " teenager drinks without joint, Duo Chengshui.Lid wine is the liquid of water paddy, and wine enters middle Jiao, class of must seeking common ground, therefore directly walks blood system.”……。Also there are many research in modern times, are summed up, and think that this pathogenesis is: deficiency of spleen-QI and stomach-QI, phlegm resistance, water is wet to stop gathering, disharmony between QI and blood, qi depression to blood stasis etc.Wherein wine impairing the liver spleen, accumulatively wet raise phlegm are the key of morbidity, and ferritic innate deficiency, weakness of the spleen and stomach for morbidity this.Generally be divided into initial stage, mid-term, phase in late period three clinically.
For ADL, Chinese medicine mainly adopts typing opinion to control and specially side's treatment, single medicine effective component extracts utilization be also in the animal experiment study stage.Typing opinion controls: clinical have this disease to be divided into three types, four types, five types etc. to carry out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.As Qian Haiqing is divided into three kinds of pattern of syndrome alcoholic liver disease, be substantially square with clearing away heat,cooling blood and removing toxin soup.Dialectical for alcoholic liver disease Accumulation of Dampness Heat and Blood Stasis, stagnation of phlegm-damp, stagnation of QI-blood, the deficiency of both qi and yin blood stasis of being divided into is hindered network four type by Zhuan Qianyou, respectively with different prescriptions treatment treatment.Alcoholic liver disease is divided into five kinds of pattern of syndrome etc. by Chen Yu etc.Special side's treatment: it is reported, has many specially sides evident in efficacy, and as Du Danfeng soup treatment alcoholic liver disease 32 example of neutralizing the effect of alcoholic drinks, total effective rate is 69.7%.Li Youtian etc. are through clinical observation, and confirm to take the patient from intending relieving alcoholism and protecting the liver drink, curative effect is better than the patient of single use of western medicine treatment.40 routine alcoholic hepatitis patients are treated in the wine liver spirit such as Zhao Dianfa, and therapeutic outcome shows it and has clear improvement to patient's liver function index.The routine alcoholic hepatitis of QiReLiShi herbs compound treatment 30 such as Zhang Shijun, obtains good therapeutic effect.Qiao Zuoxian facilitating alcohol metabolism and protecting liver soup treatment alcoholic liver disease 42 example, total effective rate reaches 88.1%.Wei Caixiang selects spleen invigorating promoting blood circulation and detoxication soup to treat alcoholic liver disease 40 example, by efficacy analysis, proves that this side has clear improvement the effect of the symptom of patients with alcoholic liver disease, sign and liver function.Li Xiaolin etc. achieve satisfactory effect with Radix Puerariae Yin and detoxification soup treatment alcoholic liver disease 43 example.In recent years, extensive and deep research is carried out to the Chinese medicine with resisting alcoholic hepatic injury, ited is desirable to by the mechanism of action of these Chinese medicine ingredients clear and definite, the mechanism of action of large compound recipe to be studied better and develop the resisting alcoholic liver injury medicament having more curative effect.No matter Chinese medicine is that typing opinion is controlled, or all there is good therapeutic effect the aspect such as application of specially side's treatment and single medicine effective component extracts.
Summary of the invention
Technical scheme of the present invention there is provided a kind of pharmaceutical composition for the treatment of alcoholic liver disease newly, and another technical scheme of the present invention there is provided preparation method and the purposes of this pharmaceutical composition.
The invention provides a kind of pharmaceutical composition for the treatment of alcoholic liver disease, it is the preparation be prepared from by the crude drug of following weight proportioning:
Flos puerariae lobatae 172-258 part, Radix Codonopsis 128.8-193.2 part, Rhizoma Atractylodis Macrocephalae 85.6-128.4 part, Poria 85.6-128.4 part, Radix Bupleuri 85.6-128.4 part, Radix Paeoniae Alba 128.8-193.2 part, Radix Salviae Miltiorrhizae 128.8-193.2 part, Rhizoma Polygoni Cuspidati 128.8-193.2 part, Rhizoma Alismatis 128.8-193.2 part, Fructus Crataegi 128.8-193.2 part, Penthorum chinense 128.8-193.2 part, Semen Hoveniae (Fructus Hoveniae) 128.8-193.2 part, Radix Glycyrrhizae 43.2-64.8 part.
Further preferably, it is the preparation be prepared from by the crude drug of following weight proportioning:
Flos puerariae lobatae 215 parts, Radix Codonopsis 161 parts, the Rhizoma Atractylodis Macrocephalae 107 parts, 107 parts, Poria, Radix Bupleuri 107 parts, the Radix Paeoniae Alba 161 parts, Radix Salviae Miltiorrhizae 161 parts, Rhizoma Polygoni Cuspidati 161 parts, Rhizoma Alismatis 161 parts, Fructus Crataegi 161 parts, Penthorum chinense 161 parts, Semen Hoveniae (Fructus Hoveniae) 161 parts, 54 parts, Radix Glycyrrhizae.
Wherein, described Fructus Crataegi is Fructus Crataegi.
Pharmaceutical composition of the present invention is by the protogenic medicinal powder of Flos puerariae lobatae, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Bupleuri, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Rhizoma Alismatis, Fructus Crataegi, Penthorum chinense, Semen Hoveniae (Fructus Hoveniae), Radix Glycyrrhizae, or water or extractive with organic solvent are active component, add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
Wherein, described preparation is tablet, capsule, pill, granule, oral liquid.
Present invention also offers a kind of method preparing described pharmaceutical composition, it comprises the steps:
A, take the crude drug of each weight proportion;
B, get Flos puerariae lobatae, Radix Salviae Miltiorrhizae powder is broken into coarse powder, adds alcohol dipping, percolation, collect percolate, reclaim ethanol, be condensed into fluid extract;
Medicinal residues and all the other crude drug of c, b step are soaked, decoct, collecting decoction, filter, filtrate reduced in volume, to relative density 1.02-1.05 (80 DEG C), leaves standstill, and gets supernatant and adds fluid extract prepared by b step, be evaporated to the extractum of relative density 1.20-1.25 (80 DEG C), add pharmaceutically acceptable adjuvant or complementary composition and be prepared into pharmaceutically conventional preparation.
Present invention also offers the purposes of described pharmaceutical composition in the medicine of preparation treatment alcoholic liver disease.
Present invention also offers described pharmaceutical composition preparing relieving alcoholic intoxication removing toxic substances, the purposes shortened in the medicine of relieving alcoholic intoxication time, alcoholic fatty liver or alcoholic hepatitis.
Present invention also offers the purposes of described pharmaceutical composition in the medicine preparing invigorating the spleen and relieving depression of liver-QI.
Present invention also offers the purposes of described pharmaceutical composition in the medicine preparing clearing away heat-damp and promoting diuresis.
Alcoholic liver disease thinks this disease " alcoholic strength is damp and hot poisonous, easy impairing the liver spleen " on pathogenesis; " alcoholic intoxication, hepatoprotective spleen, treating both the principal and the secondary aspects of a disease at the same time " is advocated in treatment.For the understanding of " poison ", think exceptionally poison and endogenous toxin.Outer poison and wine is a kind of special toxic dampness and heat inherently, and excessive drinking causes Shi Re Bing Pian and pents up in vivo.The generation of endogenous toxin is then, after entering human body because of ethanol, can produce a series of metabolite again in vivo through metabolism, as acetaldehyde, acetic acid, purine, and endotoxin.These metabolic wastes are piled up rear as do not drained in time in vivo, and will cause damage to each organ of human body, be exactly the most directly wherein liver and taste, alcoholic intoxication needs the heresy of the damp and hot alcoholism of eliminating pathogens by phlegm elimination and purgation respectively.Medicine material prescription of the present invention is made up of pure Chinese medicines of 13 taste such as Flos puerariae lobatae, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Polygoni Cuspidati, Rhizoma Alismatis, Herba Lycopi, Semen Hoveniae (Fructus Hoveniae), Fructus Crataegi, Penthorum chinense, and wherein, Flos puerariae lobatae is amusing and relieves the effect of alcohol for monarch drug; Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Poria invigorating spleen to remove dampness, Radix Bupleuri, the Radix Paeoniae Alba is soothing the liver is ministerial drug; Herba Lycopi, Radix Salviae Miltiorrhizae, Fructus Crataegi blood circulation promoting and blood stasis dispelling eliminating stagnation, Rhizoma Polygoni Cuspidati, Rhizoma Alismatis, Penthorum chinense divide sharp defecation, clearing away heat-damp and promoting diuresis, and relieving restlessness is quenched the thirst, Semen Hoveniae (Fructus Hoveniae) alcoholic intoxication, profit defecation, it is adjuvant drug altogether that relieving restlessness is quenched the thirst, the common merit embodying " relieving alcoholic intoxication removing toxic substances, invigorating the spleen and relieving depression of liver-QI, clearing away heat-damp and promoting diuresis " in full side.
Medicine of the present invention is used for because of alcohol abuse and the disease such as mild alcoholic liver disease, alcoholic fatty liver and alcoholic hepatitis caused by relying on, and has good to relieve the effect of alcohol, protect the liver and effect for reducing fat, is used for the treatment of alcoholic liver disease, evident in efficacy.In addition, medicine of the present invention obviously can also shorten relieving alcoholic intoxication time about 2 hours, and efficacy stability is reliable, is convenient for carrying and takes, provide a kind of selection newly for clinical.
Detailed description of the invention
The preparation of embodiment 1 medicinal granule of the present invention
[prescription] Flos puerariae lobatae 215g, Radix Codonopsis 161g, Rhizoma Atractylodis Macrocephalae 107g, Poria 107g, Radix Bupleuri 107g, Radix Paeoniae Alba 161g, Radix Salviae Miltiorrhizae 161g, Rhizoma Polygoni Cuspidati 161g, Rhizoma Alismatis 161g, Fructus Crataegi (life) 161g, Penthorum chinense 161g, Semen Hoveniae (Fructus Hoveniae) 161g, Radix Glycyrrhizae 54g, dextrin 800g; Make 1000g
13 tastes more than [method for making], Flos puerariae lobatae, Radix Salviae Miltiorrhizae powder are broken into coarse powder, with 8 times amount 60% alcohol dipping 12 hours, percolation, collect percolate, reclaim ethanol, be condensed into fluid extract; Ten Herba indigoferae Pseudotinctoriae such as medicinal residues and all the other Radix Codonopsis add recipe quantity 12 times amount water soaking 1 hour, decoct 3 times, each 1 hour, collecting decoction, filter, filtrate reduced in volume, to relative density 1.02 ~ 1.05 (80 DEG C), leaves standstill 12 hours, get supernatant and add above-mentioned fluid extract, be evaporated to the extractum of relative density 1.20-1.25 (80 DEG C), granulate with dextrin, granulate, subpackage, to obtain final product.
The preparation of embodiment 2 medicine capsule of the present invention
Get crude drug: Flos puerariae lobatae 172g, Radix Codonopsis 128.8g, Rhizoma Atractylodis Macrocephalae 85.6g, Poria 85.6g, Radix Bupleuri 85.6g, Radix Paeoniae Alba 128.8g, Radix Salviae Miltiorrhizae 128.8g, Rhizoma Polygoni Cuspidati 128.8g, Rhizoma Alismatis 128.8g, Fructus Crataegi 128.8g, Penthorum chinense 128.8g, Semen Hoveniae (Fructus Hoveniae) 128.8g, Radix Glycyrrhizae 43.2g; Extract by the method for embodiment 1, granulate, encapsulated, obtain capsule.
The preparation of embodiment 3 medicine oral liquid of the present invention
Get crude drug: Flos puerariae lobatae 258g, Radix Codonopsis 193.2g, Rhizoma Atractylodis Macrocephalae 128.4g, Poria 128.4g, Radix Bupleuri 128.4g, Radix Paeoniae Alba 193.2g, Radix Salviae Miltiorrhizae 193.2g, Rhizoma Polygoni Cuspidati 193.2g, Rhizoma Alismatis 193.2g, Fructus Crataegi 193.2g, Penthorum chinense 193.2g, Semen Hoveniae (Fructus Hoveniae) 193.2g, Radix Glycyrrhizae 64.8g, after extracting by the method for embodiment 1, be prepared into oral liquid.
Beneficial effect of the present invention is proved below by way of concrete clinical trial.
The clinical trial of test example 1 Drug therapy alcoholic liver disease of the present invention
1 data and method
1.1 physical data select in March, 2014 ~ 2014, the courts liver and gall internal clinic in year November and inpatient to amount to 30 examples, outside eliminating viral hepatitis, autoimmune liver disease, drug-induced liver disease and non-alcoholic fatty liver disease etc., be all male patient, the equal >5 of history of drinking history, the equal >40g of drinking amount every day.Two groups of patients no difference of science of statistics in age, degree of being addicted to drink, course of disease length, state of an illness weight, liver function index etc., has comparability (P>0.05).
The alcoholic liver disease diagnostic criteria that 1.2 Western medicine diagnose standards are formulated with reference to Chinese Medical Association's hepatology branch fatty liver and alcoholic liver disease group is drafted.(1) patient has long-term history of drinking history, generally more than 5 years, amounts to ethanol amount: male >40g/d, women >20g/d, or has heavy drinking history in 2 weeks, amount to ethanol amount >80g/d; (2) after alleviating alcohol addiction, serum aspartate amino transferase, alanine aminotransferase, γ mono-glutamyl transpeptidase obviously decline, and the liver of enlargement obviously reduces in 1 week, substantially in 4 weeks recover normal; (3) have that weak, appetite in various degree declines, hepatic region feeling of distension and oppression or dull pain, or the obvious enlargement of liver; (4) B ultrasonic shows fatty liver, and in liver, blood vessel display is unintelligible or very thin, and liver trailing edge echo is weakened; (5) cT checks and shows: liver density generally reduces; (6) non-alcoholic fatty liver disease and merge the hepatic injury etc. that HBV or HCV infection, medicine or Developmental and Metabolic Disorder cause except.
1.3 Therapeutic Method give medicinal granule of the present invention that patient prepares by embodiment 1 method (relieving the effect of alcohol granule hereinafter referred to as: Pueraria lobota Huang), 1 bag/time, three times on the one, 3 months courses for the treatment of
1.4 criterions of therapeutical effect are formulated with reference to related documents.Effective: terminate rear clinical symptoms and sign the course for the treatment of and improve obviously, the liver functions such as AST, ALT, GGT, TBiL recover normal substantially; Effective: Clinical symptom and sign takes a turn for the better, obviously declining before AST, ALT comparatively treat, as treated front AST and ALT>2.5 times upper limits of normal person, dropping to below 1.25 times of upper limits of normal.More than 40% is declined before GGT, TBiL comparatively treat; Invalid: symptom and sign is not improved, without obviously declining before AST, ALT, GGT, TBiL comparatively treat.
2 statistical analysis
All data input computers adopt SPSSl7.0 software to analyze, measurement data mean ± standard deviation
represent, and adopt t inspection rate to compare, P<0.05 is that difference has statistical significance.
3 results
The 3.1 Pueraria lobota Huangs granule therapy efficacy result that relieves the effect of alcohol is shown in (table 1)
Table 1 Pueraria lobota Huang relieves the effect of alcohol granule therapy efficacy result [n (%)]
Relieve the effect of alcohol granule therapy Patients Before And After liver function, blood fat of 3.2 Pueraria lobota Huangs compares and sees (table 2)
Relieve the effect of alcohol granule therapy Patients Before And After liver function, blood fat of table 2 Pueraria lobota Huang compares
Note: compare with before and after group treatment: p<0.05
3.3 liang of group adverse reactions of patients and compliance compare patient and complete treatment all on time, occurred that compliance is poor during this period, to a certain degree affecting treatment, do not finding that this Therapeutic Method has obvious toxic and side effects except in some patients treatment.
Proved by above-mentioned clinical trial, medicine of the present invention is used for the treatment of alcoholic liver disease, and effective percentage is high, and drug effect is clear and definite.
Claims (10)
1. treat a pharmaceutical composition for alcoholic liver disease, it is characterized in that: it is the preparation be prepared from by the crude drug of following weight proportioning:
Flos puerariae lobatae 172-258 part, Radix Codonopsis 128.8-193.2 part, Rhizoma Atractylodis Macrocephalae 85.6-128.4 part, Poria 85.6-128.4 part, Radix Bupleuri 85.6-128.4 part, Radix Paeoniae Alba 128.8-193.2 part, Radix Salviae Miltiorrhizae 128.8-193.2 part, Rhizoma Polygoni Cuspidati 128.8-193.2 part, Rhizoma Alismatis 128.8-193.2 part, Fructus Crataegi 128.8-193.2 part, Penthorum chinense 128.8-193.2 part, Semen Hoveniae (Fructus Hoveniae) 128.8-193.2 part, Radix Glycyrrhizae 43.2-64.8 part.
2. pharmaceutical composition according to claim 1, is characterized in that: it is the preparation be prepared from by the crude drug of following weight proportioning:
Flos puerariae lobatae 215 parts, Radix Codonopsis 161 parts, the Rhizoma Atractylodis Macrocephalae 107 parts, 107 parts, Poria, Radix Bupleuri 107 parts, the Radix Paeoniae Alba 161 parts, Radix Salviae Miltiorrhizae 161 parts, Rhizoma Polygoni Cuspidati 161 parts, Rhizoma Alismatis 161 parts, Fructus Crataegi 161 parts, Penthorum chinense 161 parts, Semen Hoveniae (Fructus Hoveniae) 161 parts, 54 parts, Radix Glycyrrhizae.
3. pharmaceutical composition according to claim 1 and 2, is characterized in that: described Fructus Crataegi is Fructus Crataegi.
4. the pharmaceutical composition according to claim 1-3 any one, it is characterized in that: it is by the protogenic medicinal powder of Flos puerariae lobatae, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Bupleuri, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Rhizoma Alismatis, Fructus Crataegi, Penthorum chinense, Semen Hoveniae (Fructus Hoveniae), Radix Glycyrrhizae, or water or extractive with organic solvent are active component, add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
5. pharmaceutical composition according to claim 4, is characterized in that: described preparation is tablet, capsule, pill, granule, oral liquid.
6. prepare a method for the pharmaceutical composition described in claim 1-5 any one, it comprises the steps:
A, take the crude drug of each weight proportion;
B, get Flos puerariae lobatae, Radix Salviae Miltiorrhizae powder is broken into coarse powder, adds alcohol dipping, percolation, collect percolate, reclaim ethanol, be condensed into fluid extract;
Medicinal residues and all the other crude drug of c, b step are soaked, decoct, collecting decoction, filter, filtrate reduced in volume is to relative density 1.02-1.05,80 DEG C of surveys, leave standstill, get supernatant and add fluid extract prepared by b step, be evaporated to relative density 1.20-1.25,80 DEG C of extractum surveyed, add pharmaceutically acceptable adjuvant or complementary composition is prepared into pharmaceutically conventional preparation.
7. the purposes of the pharmaceutical composition described in claim 1-5 any one in the medicine of preparation treatment alcoholic liver disease.
8. the pharmaceutical composition described in claim 1-5 any one preparing relieving alcoholic intoxication removing toxic substances, the purposes shortened in the medicine of relieving alcoholic intoxication time, alcoholic fatty liver or alcoholic hepatitis.
9. the purposes of the pharmaceutical composition described in claim 1-5 any one in the medicine preparing invigorating the spleen and relieving depression of liver-QI.
10. the purposes of the pharmaceutical composition described in claim 1-5 any one in the medicine preparing clearing away heat-damp and promoting diuresis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510034267.7A CN104644915A (en) | 2015-01-22 | 2015-01-22 | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510034267.7A CN104644915A (en) | 2015-01-22 | 2015-01-22 | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104644915A true CN104644915A (en) | 2015-05-27 |
Family
ID=53236885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510034267.7A Pending CN104644915A (en) | 2015-01-22 | 2015-01-22 | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104644915A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105169215A (en) * | 2015-07-15 | 2015-12-23 | 济南大学 | Traditional Chinese medicine composition for treating alcoholic fatty liver |
| CN105412487A (en) * | 2015-12-31 | 2016-03-23 | 青岛昌安达药业有限公司 | Traditional Chinese medicine used for treating alcoholic liver diseases |
| CN105999212A (en) * | 2016-05-13 | 2016-10-12 | 无限极（中国）有限公司 | Composition having alcohol effect dispelling effect and preparation method and application thereof |
| CN107029014A (en) * | 2017-06-16 | 2017-08-11 | 江苏省农业科学院 | Prevent and treat Chinese herb compound powder of pig bacterial endotoxin disease and its preparation method and application |
| CN110742935A (en) * | 2019-12-10 | 2020-02-04 | 上海市普陀区中心医院 | Application of traditional Chinese medicine composition in preparation of medicine for treating chronic alcoholic steatohepatitis |
| CN111956715A (en) * | 2020-07-07 | 2020-11-20 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Medicine for treating alcoholic liver disease and preparation method thereof |
| CN113398225A (en) * | 2021-07-12 | 2021-09-17 | 河南省中医院（河南中医药大学第二附属医院） | Traditional Chinese medicine for alcoholic hepatic fibrosis |
| CN115282181A (en) * | 2022-08-12 | 2022-11-04 | 江西中医药大学 | Application of pueraria flower extract |
| CN118320043A (en) * | 2024-06-13 | 2024-07-12 | 长春中医药大学 | Spleen-strengthening, vein-relaxing and turbidity-reducing composition for treating non-alcoholic steatohepatitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125185A (en) * | 2006-08-16 | 2008-02-20 | 孙瑞山 | Traditional Chinese medicine for treating fatty liver |
| CN101401920A (en) * | 2008-11-06 | 2009-04-08 | 张晨 | Traditional Chinese medicine preparation for treating fatty liver |
| CN103142812A (en) * | 2013-03-29 | 2013-06-12 | 山东省中医药研究院 | Traditional Chinese medicine for preventing and treating alcoholic liver injury and preparation method of traditional Chinese medicine |
-
2015
- 2015-01-22 CN CN201510034267.7A patent/CN104644915A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125185A (en) * | 2006-08-16 | 2008-02-20 | 孙瑞山 | Traditional Chinese medicine for treating fatty liver |
| CN101401920A (en) * | 2008-11-06 | 2009-04-08 | 张晨 | Traditional Chinese medicine preparation for treating fatty liver |
| CN103142812A (en) * | 2013-03-29 | 2013-06-12 | 山东省中医药研究院 | Traditional Chinese medicine for preventing and treating alcoholic liver injury and preparation method of traditional Chinese medicine |
Non-Patent Citations (1)
| Title |
|---|
| 殷晓轩，等。: ""酒精性肝病中医用药规律探讨"", 《中国实验方剂学杂志》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105169215A (en) * | 2015-07-15 | 2015-12-23 | 济南大学 | Traditional Chinese medicine composition for treating alcoholic fatty liver |
| CN105412487A (en) * | 2015-12-31 | 2016-03-23 | 青岛昌安达药业有限公司 | Traditional Chinese medicine used for treating alcoholic liver diseases |
| CN105999212A (en) * | 2016-05-13 | 2016-10-12 | 无限极（中国）有限公司 | Composition having alcohol effect dispelling effect and preparation method and application thereof |
| CN107029014A (en) * | 2017-06-16 | 2017-08-11 | 江苏省农业科学院 | Prevent and treat Chinese herb compound powder of pig bacterial endotoxin disease and its preparation method and application |
| CN110742935A (en) * | 2019-12-10 | 2020-02-04 | 上海市普陀区中心医院 | Application of traditional Chinese medicine composition in preparation of medicine for treating chronic alcoholic steatohepatitis |
| CN111956715A (en) * | 2020-07-07 | 2020-11-20 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Medicine for treating alcoholic liver disease and preparation method thereof |
| CN113398225A (en) * | 2021-07-12 | 2021-09-17 | 河南省中医院（河南中医药大学第二附属医院） | Traditional Chinese medicine for alcoholic hepatic fibrosis |
| CN115282181A (en) * | 2022-08-12 | 2022-11-04 | 江西中医药大学 | Application of pueraria flower extract |
| CN118320043A (en) * | 2024-06-13 | 2024-07-12 | 长春中医药大学 | Spleen-strengthening, vein-relaxing and turbidity-reducing composition for treating non-alcoholic steatohepatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104644915A (en) | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition | |
| CN102755594B (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN104840871A (en) | Traditional Chinese medicine for treating alcoholic liver injury | |
| CN105561006A (en) | Food, health care food or medicine composition with alcohol effect dispelling function and preparation method and application thereof | |
| CN104815316A (en) | Traditional Chinese medicine preparation for treating acute or chronic pancreatitis and preparation method thereof | |
| CN105497811A (en) | Traditional Chinese medicine composition for treating liver cirrhosis and preparation technology thereof | |
| CN101011470B (en) | Traditional Chinese medicine compound composition for treating hepatitis | |
| CN105943705A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN100369622C (en) | Blood fat-reducing Chinese medicine and preparation method thereof | |
| CN102764411B (en) | Drug composite for curing jaundice and preparation method thereof | |
| CN113456728A (en) | A Chinese medicinal oral liquid for treating chronic hepatitis B, and its preparation method | |
| CN101695562A (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN112755084A (en) | Anti-hepatic fibrosis traditional Chinese medicine compound composition and application thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN110575521A (en) | Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application | |
| CN103212033B (en) | Drug composition for treating viral hepatitis | |
| CN104435239A (en) | Traditional Chinese medicinal composition for preventing and treating hepatitis and preparation method of traditional Chinese medicinal composition | |
| CN100496590C (en) | Medicine for treating fatty liver and its preparation method | |
| CN114272349A (en) | Traditional Chinese medicine composition for tonifying spleen and nourishing liver and preparation method and application thereof | |
| CN103007204A (en) | Chinese medicinal composition for treating hepatofibrosis | |
| CN102406906A (en) | Traditional Chinese medicine composition for treating acute hepatitis B | |
| CN102743477A (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150527 |
|
| RJ01 | Rejection of invention patent application after publication |